Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. (IMDX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
imdx · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$12.00
+109.8% upside
Low
$12.00
Median: $12 · Last Close: $5.72
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.68 | ↓ 0.62% |
1-day model range: $5.58–$5.79. Peak: $5.79 (-0.62%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $4 | -26.5% |
| 2028 | $4 | -36.2% |
| 2029 | $3 | -40.4% |
| 2030 | $3 | -42.4% |
| 2031 | — | -43.4% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · IMDX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-02-17 | Lake Street | Maintains | Buy→Buy |
| 2025-11-11 | Needham | Maintains | Buy→Buy |
| 2025-08-18 | Needham | Maintains | Buy→Buy |
| 2025-05-21 | Lake Street | Maintains | Buy→Buy |
| 2025-05-13 | Needham | Maintains | Buy→Buy |
| 2025-04-08 | Needham | Maintains | Buy→Buy |
| 2025-03-26 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2025-03-25 | Needham | Maintains | Buy→Buy |
| 2025-03-25 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2023-08-23 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
Wall Street analysts have recently issued updated ratings on Insight Molecular Diagnostics Inc. (IMDX) stock. Of the recent 45 rating actions, 1 were upgrades and 6 were downgrades. 11 analysts currently cover IMDX.
Analyst Recommendation Trends
IMDX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 76.7% YoY
Revenue Next Year
$3M
↑ 545.0% YoY
EPS This Year
$-2.74
EPS Next Year
$-1.15
↓ 58.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast IMDX EPS of $-2.74 for the current fiscal year, based on estimates from 1 analysts. The IMDX revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The IMDX stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus IMDX price target is $12.00 (+109.8% upside), with an analyst consensus of Buy.
The IMDX short-term stock prediction for tomorrow is $5.68 (-0.62%). The IMDX stock price prediction for 2027 estimates an average of $4. The IMDX stock prediction for 2030 projects a range of $3–$4.
Insight Molecular Diagnostics Inc. trades on NASDAQ under the ticker IMDX. The IMDX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 64% of covering analysts.
Frequently asked questions
IMDX forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month IMDX price target is $12.00, with a high forecast of $12.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +109.8% potential upside from the current price of $5.72.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.